Tue.Feb 15, 2022

article thumbnail

Pharma pollution ‘threatens world environment, health’; study

pharmaphorum

One in four of the world’s rivers are polluted with potentially toxic levels of pharma compounds, according to a new study. The findings point to a “threat to environmental and global health,” say the scientists, who found that paracetamol, antibiotics epilepsy drug carbamazepine, metformin for diabetes and other compounds like caffeine and nicotine were found in samples from around the world – including in Antarctica.

article thumbnail

Clinical research trends include increased emphasis on study design: Advarra

Outsourcing Pharma

An expert from the institutional review board services company advises what trends to look for in the clinical trial industry over the course of coming months.

105
105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pushing the right buttons for transformative digital health

pharmaphorum

Digital health and technologies offer a wealth of opportunities, but digital needs to become part of a company’s DNA to achieve transformation. Rodamni Peppa, Boston Scientific’s vice-president for business strategy & commercial excellence for Europe, the Middle East and Africa, gives insight into a four-year digital journey with Dr Paul Tunnah at the 2021 Frontiers Health conference in Milan.

59
article thumbnail

Domainex, Parkinson’s UK team up to advance neuroinflammation program

Outsourcing Pharma

The institute and the research/support organization will collaborate on development of novel therapies aimed at treating the central nervous system disorder.

97
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Amgen eyes pancreatic cancer use for its pathfinder KRAS drug

pharmaphorum

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer, as it tries to extend the label for the first-in-class drug beyond its current use in non-small cell lung cancer (NSCLC). Data from the CodeBreaK 100 phase 1/2 trial showed “encouraging and clinically meaningful anticancer activity” for Lumakras (sotorasib) in patients with KRAS G12C-mutated advanced pancreatic cancer , including an objective response rate (ORR) of 2

article thumbnail

Scientists discover immune cell surveillance mechanism

Pharma Times

Francis Crick Institute and King’s College London collaborate to identify specialist cells which protect DNA

More Trending

article thumbnail

AI captain: £2.6M raised to develop rapid diagnostic technology

Pharma Times

Oxford university spin out company develops tech to identify viruses in seconds

56
article thumbnail

Pharma’s digital inflection point

pharmaphorum

Billed as the world’s most influential technology event, this year’s CES show saw its first ever keynote from a healthcare company when Abbott CEO Robert Ford took to the stage in Las Vegas last month. For Ford, the focus was on his company’s new range of consumer ‘biowearable’ health devices , but his appearance was also another reminder of the increasing importance of ‘digital’ in all its forms across the life sciences sector.

FDA 52
article thumbnail

ADC Cytotoxic Payloads / Warheads and Rise in its Demand

Roots Analysis

With six approved drugs, namely POLIVY (2019), LUMOXITI (2018), BESPONSA® (2017), MYLOTARG (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 300 candidates in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) have emerged as a promising class of therapeutics for the treatment of various disease indications.

52
article thumbnail

Digital health firm Bia Care extends NHS menopause partnership

pharmaphorum

Digital health startup Bia Care has been awarded additional funding from the NHS to extend the rollout of its virtual clinic providing remote care for women going through the menopause. The London-based company launched the digitally-enabled service last year, allowing women to book an appointment, have a group online consultation with a doctor, get a personalised plan for managing menopause and – if needed – get treatments delivered to their homes.

75
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Bringing in Light Genome Editing Techniques: ZFN, TALEN and Meganucleases

Roots Analysis

Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. With the development of a variety of versatile DNA modulation technologies such as include zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs) and clustered regularly interspaced short palindromic repeats (CRISPR), genetic enginee

52
article thumbnail

Robert Califf confirmed as FDA commissioner in tight vote

pharmaphorum

It’s official – President Joe Biden’s choice for FDA commissioner, Robert Califf, has been confirmed to the role after a narrow 50 to 46 vote in the Senate that relied on crossover Republican votes. That bipartisan support proved to be essential, with six Republican senators casting their lot for Califf to outweigh the five Democrats who voted against him.

FDA 52